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Abstract
Mechanically ventilated, intubated patients are at increased risk for tracheal colonization with bacterial pathogens
that may progress to heavy bacterial colonization, ventilator-associated tracheobronchitis (VAT), and/or ventilator-
associated pneumonia (VAP). Previous studies report that 10 to 30 % of patients with VAT progress to VAP,
resulting in increased morbidity and significant acute and chronic healthcare costs. Several natural history
studies, randomized, controlled trials, and a meta-analysis have reported antibiotic treatment for VAT can
reduce VAP, ventilator days, length of intensive care unit (ICU) stay, and patient morbidity and mortality. We
discuss early diagnostic criteria, etiologic agents, and benefits of initiating, early, appropriate intravenous or
aerosolized antibiotic(s) to treat VAT and reduce VAP, to improve patient outcomes by reducing lung damage,
length of ICU stay, and healthcare costs.
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Background
Ventilator-associated respiratory infections (VARI) often
begin with bacterial colonization that may progress to
include ventilator-associated tracheobronchitis (VAT)
and ventilator-associated pneumonia (VAP) diagnosed
after 48 h of intubation [1–10]. VAT and VAP have
similar clinical signs of fever, leukocytosis, purulent
secretions, and positive bacterial cultures, except VAP
requires a new infiltrate on chest radiograph. Rates of
progression from VAT to VAP range between 7 and 30 %
[3–7]. VAP mortality rates are 20 to 50 % with healthcare
costs of $20,000 to $40,000 per patient. Inappropriate
antibiotic therapy for VAP increases patient mortality
(p = 0.001), hospital mortality (p < 0.0001), ventilator days
(16 versus 7, p < 0.0005), intensive care unit (ICU) days
(14 versus 8, p = 0.02), and hospital days (42 versus 28,
p = 0.04) [4].
VAT is an unappreciated but important early clinical
condition in ventilated patients which has been linked to
VAP, resulting in significant patient morbidity and mor-
tality [3–7]. The incidence of VAT ranges from 2.7 to
11.5 % in randomized trials and 7 to 30 % of VAT pa-
tients will progress to VAP. Gram-negative pathogens
are responsible for >75 % of the episodes and virulence
is greater for Pseudomonas aeruginosa isolates with
toxins or other multi-drug resistant (MDR) pathogens
that require early, effective, intravenous or aerosolized
antibiotic therapy, as well as re-evaluation of non-
responders to antibiotic therapy.
Several studies have compared outcomes of ventilated
patients, focusing on increased ventilator days and
length of ICU stay for VAT and VAP patients. In
addition, numerous studies have demonstrated improved
patient outcomes in VAT patients treated with appropri-
ate antibiotics [3–9]. Nseir et al. [6] studied 58 VAT
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patients randomly assigned to intravenous antibiotic
therapy (n = 22) versus no therapy (n = 36). The antibiotic-
treated group had more mechanical ventilation-free days
(12 versus 2, p < 0.001), reduced VAP (13 versus 47 %,
p = 0.01), and significantly lower ICU mortality (18 versus
47 %, p = 0.047).
Aerosolized antibiotic therapy for VAT and VAP has
attracted increased interest. It is administered using an
in-line nebulizer and has the advantage over intravenous
therapy of being able to deliver a higher concentration
of antibiotics into all parts of the lung, which can
decrease bacterial lung burden, pulmonary damage and
associated complications, as well as Clostridium difficile
colitis resulting from intravenous antibiotic therapy. Of
note, Palmer and Smaldone [9] reported decreased
respiratory infections in VAT patients treated with
aerosolized antibiotics; 26 of 27 organisms were eradi-
cated compared with placebo (p < 0.0001) and 14 out of
16 patients were cured (p < 0.001).
Serial endotracheal aspirate (ETA) surveillance sam-
ples can help clinicians identify numbers of pathogens
and the antibiotic sensitivity profile needed to initiate
earlier appropriate antibiotic therapy to decrease
colonization, VAT, and VAP [3–8]. In “thinking out-
side the box”, serial ETA “surveillance cultures” can
be a valuable clinical tool to monitor the levels of air-
way colonization with bacterial pathogens and facili-
tate use of pre-emptive, targeted antibiotic therapy for
VAT to reduce VAP, ventilator days, lung bacterial
burden, and risk of post-traumatic stress disorder or
delirium [4–13].
Depuydt and coworkers [8] demonstrated the benefit
of serial ETA surveillance cultures for identifying MDR
pathogens and earlier appropriate antibiotic therapy for
VAP rather than empiric broad spectrum antibiotics
with de-escalation. However, the increased availability of
rapid microbiologic diagnostic methods for identifying
and treating specific pathogens and the use of antibiotic
sensitivity profiles of bacteria in ETA samples—using
“matrix-assisted laser desorption ionization mass spec-
trometry (MALDI-TOF), which can facilitate early,
appropriate pre-emptive antibiotic therapy for VAT and/
or VAP—will improve patient outcomes and reduce
healthcare costs.
Ventilated ICU patients are invariably complicated,
often elderly, critically ill patients with underlying acute
and or chronic diseases or post-surgery and who are at
increased risk for VARI, an “infection vortex” with com-
plications such as lung bacterial burden, damage that in-
creases host debility, and delirium or post traumatic
stress disorder, which may linger for months or years,
resulting in hospital readmissions and enormous health-
care costs [12–14]. For example, Unroe et al. [14] stud-
ied 99 ventilated patient survivors from five ICUs at
Duke who were carefully followed for one year after dis-
charge. These patients underwent 150 hospital readmis-
sions and multiple transitions of care between acute,
chronic, and long-term care or rehabilitation. Of note is
that one year following hospital discharge, only 9 % of
the 99 study patients were living independently with es-
timated costs of $3.5 million per survivor. All of these
poor outcomes underscore the importance of early and
effective antibiotic therapy to reduce lung bacterial bur-
den and to make an effort to improve patient outcomes
in ventilated patients.
Conclusions
We recommend use of VAP prevention strategies
with a focus on earlier diagnosis and use of pre-
emptive, appropriate antibiotic therapy based on clin-
ical signs and microbiologic evidence of heavy endo-
tracheal colonization, VAT, or VAP. This can be done
by using serial lung surveillance cultures to identify
bacterial pathogens and antibiotic sensitivity profiles,
assessing levels of bacterial colonization for the pres-
ence of more virulent strains, such as Staphylococcus
aureus or P. aeruginosa, which produce toxins, or
MDR Gram-negative bacterial pathogens. Ventilated
patients should undergo careful monitoring to assess
the need for early antibiotic therapy and so the endo-
tracheal tube is removed as soon as possible to re-
duce leakage around the endotracheal tube cuff or
biofilm emboli from the endotracheal tube lumen.
Careful monitoring is also needed to assess the im-
pact of early antibiotic therapy, the use of sedation
vacations, and “walk to wean” programs for better pa-
tient outcomes and reduced hospital stay and associ-
ated healthcare costs. In 1895, Sir William Osler MD,
an expert on pneumonia, said “Remember how much
you don’t know”. Today, he might add “Remember
how much your care team know and can apply.”
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